Primary angiosarcoma of the breast: a literature review.

IF 2.1 4区 医学 Q3 ONCOLOGY Chinese clinical oncology Pub Date : 2024-09-05 DOI:10.21037/cco-24-16
Yidan Zhu, Shogo Nakamoto, Takahiro Tsukioki, Yuko Takahashi, Yoko Iwatani, Tsuguo Iwatani, Xinfeng Zhang, Maki Tanioka, Tadahiko Shien
{"title":"Primary angiosarcoma of the breast: a literature review.","authors":"Yidan Zhu, Shogo Nakamoto, Takahiro Tsukioki, Yuko Takahashi, Yoko Iwatani, Tsuguo Iwatani, Xinfeng Zhang, Maki Tanioka, Tadahiko Shien","doi":"10.21037/cco-24-16","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objective: </strong>Primary angiosarcoma of the breast (PBA) is an extremely rare and heterogeneous disease. PBA is difficult to diagnose and has a poor prognosis. In order to better understand the disease and provide evidence-based treatment for PBA patients, a review of the published literature in the English language was conducted.</p><p><strong>Methods: </strong>A literature review in agreement with the PRISMA protocol was conducted. Medline and Cochrane databases were searched for English articles on PBA patients in September 2023 with a predetermined strategy. The articles were categorized and assessed based on hierarchical levels of scientific evidence.</p><p><strong>Key content and findings: </strong>A total of 255 articles were identified, among these 137 publications which included 1,888 patients met the criteria for inclusion in the final analysis. No prospective, randomized trials exclusive to PBA have been recognized. This article provides an overview of the most current and comprehensive evidence concerning the epidemiology, etiology, genomic features, clinical presentations, diagnosis, treatment, and prognosis of PBA.</p><p><strong>Conclusions: </strong>Despite the fact that current evidence is largely derived from retrospective studies, database analyses, and case reports, we utilized this information to tackle important clinical questions concerning optimal patient management practices for PBA. Complete surgical excision continues to be the mainstay treatment for PBA. However, the effectiveness of adjuvant therapies is still unclear. This narrative review highlights the urgent need for more rigorously designed research to enhance the management and treatment strategies for PBA.</p>","PeriodicalId":9945,"journal":{"name":"Chinese clinical oncology","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chinese clinical oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/cco-24-16","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and objective: Primary angiosarcoma of the breast (PBA) is an extremely rare and heterogeneous disease. PBA is difficult to diagnose and has a poor prognosis. In order to better understand the disease and provide evidence-based treatment for PBA patients, a review of the published literature in the English language was conducted.

Methods: A literature review in agreement with the PRISMA protocol was conducted. Medline and Cochrane databases were searched for English articles on PBA patients in September 2023 with a predetermined strategy. The articles were categorized and assessed based on hierarchical levels of scientific evidence.

Key content and findings: A total of 255 articles were identified, among these 137 publications which included 1,888 patients met the criteria for inclusion in the final analysis. No prospective, randomized trials exclusive to PBA have been recognized. This article provides an overview of the most current and comprehensive evidence concerning the epidemiology, etiology, genomic features, clinical presentations, diagnosis, treatment, and prognosis of PBA.

Conclusions: Despite the fact that current evidence is largely derived from retrospective studies, database analyses, and case reports, we utilized this information to tackle important clinical questions concerning optimal patient management practices for PBA. Complete surgical excision continues to be the mainstay treatment for PBA. However, the effectiveness of adjuvant therapies is still unclear. This narrative review highlights the urgent need for more rigorously designed research to enhance the management and treatment strategies for PBA.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
乳腺原发性血管肉瘤:文献综述。
背景和目的:原发性乳腺血管肉瘤(PBA)是一种极其罕见的异质性疾病。PBA 诊断困难,预后较差。为了更好地了解这种疾病并为 PBA 患者提供循证治疗,我们对已发表的英文文献进行了综述:方法:按照 PRISMA 协议进行文献综述。按照预先确定的策略,在 Medline 和 Cochrane 数据库中检索了 2023 年 9 月有关 PBA 患者的英文文章。根据科学证据的层次对文章进行分类和评估:共检索到 255 篇文章,其中 137 篇符合纳入最终分析的标准,共纳入 1,888 名患者。目前尚未发现专门针对 PBA 的前瞻性随机试验。本文概述了目前有关 PBA 的流行病学、病因学、基因组特征、临床表现、诊断、治疗和预后的最全面证据:尽管目前的证据主要来自于回顾性研究、数据库分析和病例报告,但我们还是利用这些信息解决了有关PBA最佳患者管理方法的重要临床问题。完全手术切除仍然是治疗 PBA 的主要方法。然而,辅助疗法的有效性仍不明确。这篇叙事性综述强调了迫切需要进行更严格设计的研究,以加强 PBA 的管理和治疗策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
3.90
自引率
0.00%
发文量
0
期刊介绍: The Chinese Clinical Oncology (Print ISSN 2304-3865; Online ISSN 2304-3873; Chin Clin Oncol; CCO) publishes articles that describe new findings in the field of oncology, and provides current and practical information on diagnosis, prevention and clinical investigations of cancer. Specific areas of interest include, but are not limited to: multimodality therapy, biomarkers, imaging, tumor biology, pathology, chemoprevention, and technical advances related to cancer. The aim of the Journal is to provide a forum for the dissemination of original research articles as well as review articles in all areas related to cancer. It is an international, peer-reviewed journal with a focus on cutting-edge findings in this rapidly changing field. To that end, Chin Clin Oncol is dedicated to translating the latest research developments into best multimodality practice. The journal features a distinguished editorial board, which brings together a team of highly experienced specialists in cancer treatment and research. The diverse experience of the board members allows our editorial panel to lend their expertise to a broad spectrum of cancer subjects.
期刊最新文献
A case report of successful combined intra-arterial immunotherapy and cytokine genetic therapy treatment in a patient with recurrent glioblastoma. Primary angiosarcoma of the breast: a literature review. Befotertinib in first-line treatment for Chinese non-small cell lung cancer patients harboring common EGFR-mutations reveals similar efficacy to other third-generation EGFR-TKIs but somewhat different safety profile. Benefit from addition of local therapy in oligometastatic oesophageal squamous cell carcinoma. Therapeutic inhibition of isocitrate dehydrogenase mutations in glioma and cholangiocarcinoma: new insights and promises-a narrative review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1